Sign In
Buy WHTCF
Washtec Ag Earnings Calls
| Release date | May 07, 2026 |
| EPS estimate | $0.0391 |
| EPS actual | $0.0431 |
| EPS Surprise | 10.22% |
| Revenue estimate | 263.828M |
| Revenue actual | 264.75M |
| Revenue Surprise | 0.350% |
| Release date | Mar 19, 2026 |
| EPS estimate | $0.0774 |
| EPS actual | $0.146 |
| EPS Surprise | 88.19% |
| Revenue estimate | 280.491M |
| Revenue actual | 280.19M |
| Revenue Surprise | -0.108% |
| Release date | Nov 05, 2025 |
| EPS estimate | $0.0658 |
| EPS actual | $0.0117 |
| EPS Surprise | -82.30% |
| Revenue estimate | 386.396M |
| Revenue actual | 261.78M |
| Revenue Surprise | -32.25% |
| Release date | Aug 11, 2025 |
| EPS estimate | $0.0707 |
| EPS actual | $0.0352 |
| EPS Surprise | -50.19% |
| Revenue estimate | 353.393M |
| Revenue actual | 261.791M |
| Revenue Surprise | -25.92% |
Last 4 Quarters for Washtec Ag
Below you can see how WHTCF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 11, 2025 |
| Price on release | $3.51 |
| EPS estimate | $0.0707 |
| EPS actual | $0.0352 |
| EPS surprise | -50.19% |
| Date | Price |
|---|---|
| Aug 05, 2025 | $3.40 |
| Aug 06, 2025 | $3.45 |
| Aug 07, 2025 | $3.49 |
| Aug 08, 2025 | $3.57 |
| Aug 11, 2025 | $3.51 |
| Aug 12, 2025 | $3.49 |
| Aug 13, 2025 | $3.64 |
| Aug 14, 2025 | $3.59 |
| Aug 15, 2025 | $3.45 |
| 4 days before | 3.20% |
| 4 days after | -1.65% |
| On release day | -0.570% |
| Change in period | 1.50% |
| Release date | Nov 05, 2025 |
| Price on release | $3.47 |
| EPS estimate | $0.0658 |
| EPS actual | $0.0117 |
| EPS surprise | -82.30% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $3.74 |
| Oct 31, 2025 | $3.73 |
| Nov 03, 2025 | $3.65 |
| Nov 04, 2025 | $3.53 |
| Nov 05, 2025 | $3.47 |
| Nov 06, 2025 | $3.19 |
| Nov 07, 2025 | $3.11 |
| Nov 10, 2025 | $3.02 |
| Nov 11, 2025 | $2.97 |
| 4 days before | -7.22% |
| 4 days after | -14.50% |
| On release day | -8.10% |
| Change in period | -20.67% |
| Release date | Mar 19, 2026 |
| Price on release | $2.88 |
| EPS estimate | $0.0774 |
| EPS actual | $0.146 |
| EPS surprise | 88.19% |
| Date | Price |
|---|---|
| Mar 13, 2026 | $2.97 |
| Mar 16, 2026 | $2.97 |
| Mar 17, 2026 | $3.12 |
| Mar 18, 2026 | $3.09 |
| Mar 19, 2026 | $2.88 |
| Mar 20, 2026 | $2.75 |
| Mar 23, 2026 | $2.72 |
| Mar 24, 2026 | $2.69 |
| Mar 25, 2026 | $2.75 |
| 4 days before | -3.03% |
| 4 days after | -4.51% |
| On release day | -4.51% |
| Change in period | -7.41% |
| Release date | May 07, 2026 |
| Price on release | $3.19 |
| EPS estimate | $0.0391 |
| EPS actual | $0.0431 |
| EPS surprise | 10.22% |
| Date | Price |
|---|---|
| May 01, 2026 | $3.21 |
| May 04, 2026 | $3.18 |
| May 05, 2026 | $3.19 |
| May 06, 2026 | $3.19 |
| May 07, 2026 | $3.19 |
| May 08, 2026 | $3.04 |
| May 11, 2026 | $2.99 |
| May 12, 2026 | $2.99 |
| May 13, 2026 | $2.88 |
| 4 days before | -0.717% |
| 4 days after | -9.60% |
| On release day | -4.58% |
| Change in period | -10.25% |
Washtec Ag Earnings Call Transcript Summary of Q1 2026
WELL Health reported a strong start to fiscal 2026 with consolidated revenue of $368.3M (up 25% YoY), adjusted EBITDA of $43.1M (up 56%), and adjusted net income of $15.5M (doubling YoY). Canadian operations are the primary growth engine: Canadian clinics generated $130.3M in Q1 and are on track to materially exceed $0.5B in revenue for 2026, with clinics network now at 253 locations and 1.3M patient visits in Canada (up ~31% YoY). Wellstar (SaaS/EMR) and Healwell (AI/data) showed strong momentum — Wellstar revenue $21.8M (MRR $6.4M) and Healwell revenue $33.2M (up 316% YoY), with Healwell reporting positive adjusted EBITDA. Management highlighted three converging tailwinds (federal interoperability law Bill S-5, provincial procurement bias toward Canadian sovereign platforms, and AI adoption) that favor WELL’s integrated clinic + software + AI model. Operational highlights include AI transcription (195k fax images transcribed), 160k e-referrals/month, and >44,000 providers using Wellstar. Circle Medical had $12.8M of deferred revenue recognized in the quarter (Q2 expected to be final quarter materially impacted). The company reiterated disciplined capital allocation: parent capital focused on Canadian clinics while Wellstar, Healwell and CyberWell operate as strategically controlled platforms with minority partners/strategic reviews (including U.S. care delivery assets). WELL launched WELL Health Intelligence Platform (WIP) to unify data/AI across subsidiaries and announced WELL Research to commercialize clinic-led clinical trials; CyberWell consolidation and a planned third-party capital raise were also described. Balance sheet and liquidity: cash ~$134M, expanded senior secured credit facility to CAD 400M (plus $100M accordion), and ongoing NCIB buybacks. Management reaffirmed 2026 guidance: revenue $1.55B–$1.65B and adjusted EBITDA $175M–$185M, and said margin expansion is expected as AI/WIP and a cost optimization program take effect in H2 2026 into 2027. Key risks called out include regulatory and execution risks, cybersecurity exposure from mandated data exchange, and timing of M&A/divestitures.
